Monopar Therapeutics Inc
MNPR57.750USD
+0.870+1.53%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
384.78MCap. mercado
PérdidaP/E TTM
Más Datos de Monopar Therapeutics Inc Compañía
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Información de Monopar Therapeutics Inc
Símbolo de cotizaciónMNPR
Nombre de la empresaMonopar Therapeutics Inc
Fecha de salida a bolsaDec 19, 2019
Director ejecutivoRobinson (Chandler D)
Número de empleados16
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 19
Dirección1000 Skokie Blvd Ste 350
CiudadWILMETTE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal60091-1146
Teléfono18473880349
Sitio Webhttps://www.monopartx.com/
Símbolo de cotizaciónMNPR
Fecha de salida a bolsaDec 19, 2019
Director ejecutivoRobinson (Chandler D)
Ejecutivos de Monopar Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
148.53K
+62945.00%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
8.76K
+2589.00%
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
148.53K
+62945.00%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
8.76K
+2589.00%
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: lun., 2 de feb
Actualizado: lun., 2 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Janus Henderson Investors
19.26%
Adage Capital Management, L.P.
9.86%
Gem Pharmaceuticals LLC
9.14%
RA Capital Management, LP
7.65%
AstraZeneca PLC
5.80%
Otro
48.28%
Accionistas
Accionistas
Proporción
Janus Henderson Investors
19.26%
Adage Capital Management, L.P.
9.86%
Gem Pharmaceuticals LLC
9.14%
RA Capital Management, LP
7.65%
AstraZeneca PLC
5.80%
Otro
48.28%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
28.96%
Hedge Fund
19.01%
Corporation
14.94%
Investment Advisor
10.84%
Venture Capital
9.00%
Individual Investor
6.75%
Research Firm
0.24%
Pension Fund
0.07%
Bank and Trust
0.06%
Otro
10.12%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
123
4.56M
68.20%
+926.42K
2025Q3
99
3.34M
50.46%
+135.23K
2025Q2
76
5.07M
82.91%
-355.61K
2025Q1
72
5.03M
83.96%
+455.96K
2024Q4
54
4.84M
79.28%
+1.76M
2024Q3
40
1.90M
50.69%
+25.14K
2024Q2
43
1.96M
52.51%
+123.52K
2024Q1
46
1.91M
52.92%
+136.66K
2023Q4
44
1.88M
67.20%
+125.61K
2023Q3
42
1.87M
67.45%
+153.91K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Janus Henderson Investors
1.29M
19.26%
+115.00K
+9.81%
Sep 30, 2025
Adage Capital Management, L.P.
659.20K
9.86%
+60.00K
+10.01%
Sep 30, 2025
Gem Pharmaceuticals LLC
611.08K
9.14%
--
--
Apr 04, 2025
RA Capital Management, LP
511.21K
7.65%
--
--
Sep 30, 2025
AstraZeneca PLC
387.33K
5.8%
+387.33K
--
Oct 23, 2024
The Vanguard Group, Inc.
208.22K
3.12%
+121.73K
+140.75%
Sep 30, 2025
Wellington Management Company, LLP
231.46K
3.46%
+231.46K
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
182.63K
2.73%
-1.34K
-0.73%
Sep 30, 2025
Deerfield Management Company, L.P.
159.76K
2.39%
+159.76K
--
Sep 30, 2025
Saturn V Capital Management LP
155.37K
2.33%
+155.37K
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: mar., 2 de dic
Actualizado: mar., 2 de dic
Nombre
Proporción
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proporción0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.05%
Vanguard US Momentum Factor ETF
Proporción0.04%
iShares Russell 2000 Growth ETF
Proporción0.02%
Proshares Ultra Russell 2000
Proporción0.01%
Global X Russell 2000 ETF
Proporción0.01%
ProShares Hedge Replication ETF
Proporción0.01%
ProShares UltraPro Russell2000
Proporción0.01%
iShares Russell 2000 ETF
Proporción0.01%
Avantis US Small Cap Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
